Single Cell Multiomics Market Size, Share, Trends, Growth and Forecast 2034

Single Cell Multiomics Industry Prospective:

The global single cell multiomics market size was worth around USD 3.2 billion in 2024 and is predicted to grow to around USD 22.4 billion by 2034, with a compound annual growth rate (CAGR) of roughly 21.5% between 2025 and 2034.       

Request Free Sample

Single Cell Multiomics Market: Overview

Single-cell multiomics is a powerful, rapidly evolving method in biological research that enables scientists to examine multiple types of molecular information (omics) at the single-cell level. These types of information include genomics, transcriptomics, epigenomics, proteomics, and metabolomics. The increasing number of chronic and infectious diseases drives expansion in the industry. Investing in multiomic methods to learn more about cellular heterogeneity and treatment resistance is being driven by cancer, heart disease, diabetes, and neurological diseases.

Key Insights

• As per the analysis shared by our research analyst, the global single cell multiomics market is estimated to grow annually at a CAGR of around 21.5% over the forecast period (2025-2034).
• In terms of revenue, the global single cell multiomics market size was valued at around USD 3.2 billion in 2024 and is projected to reach USD 22.4 billion by 2034.
• The growing demand for precision medicine & biomedical research is expected to drive the single cell multiomics industry over the forecast period.
• Based on the product, the single cell genomics segment is expected to hold the largest market share over the forecast period.
• Based on the application, the oncology segment is expected to dominate the market over the projected period.
• Based on the end user, the academic and research organizations segment is expected to capture a significant revenue share during the anticipated period.
• Based on region, North America is expected to dominate the market during the forecast period.

Single Cell Multiomics Market: Growth Drivers

How will increasing demand for personalized medicine and growing disposable income assist the growth of the single cell multiomics market?

The single cell multiomics business is benefiting from expanding disposable wealth in emerging economies, as well as increased adoption of personalized medicine for genetic screening and detection. Personalized medicine has the ability to reduce the genetic and molecular complexities of diseases with high mortality rates and significant healthcare costs. This could provide vital prevention strategies as well as advice regarding disease progression, and it could help forecast morbidity, mortality, and chronic illness symptoms far in advance of the disease's course.

New single-cell platforms facilitate separation and analysis, and in some situations, both the potential growth and constraints to these technological solutions are quickly becoming apparent, stimulating researchers' interest, notably in the field of single-cell genomics. The single cell multiomics market is predicted to grow as technology advances in single-cell analysis products.

Single Cell Multiomics Market: Restraints

How do high capital & operational costs hinder the single cell multiomics market growth?

The single cell multiomics business encounters plenty of difficulties due to the high capital and operational expenditures. Depending on their setup, advanced systems like 10x Genomics' Chromium, BD Rhapsody, Mission Bio's Tapestri, and Natera's tools can cost hundreds of thousands of dollars, and occasionally more than $500,000 each. It costs an enormous amount of money to buy tools for isolating single cells, microfluidics, sequencing (like Illumina NovaSeq), and mass spectrometry (for proteomics). These tools also need a particular lab space.

Additionally, instruments require frequent calibration, have specialized maintenance contracts, and in some cases, only the manufacturer can repair them. All of these things add to the long-term cost of ownership. Some technologies need closed systems with proprietary reagents and cartridges, like 10x Genomics kits. This locks one into a vendor and costs customers more over time.

Single Cell Multiomics Market: Opportunities

Increasing technological innovation by the key market player offers a potential opportunity in the market

Increasing technological innovation by the key market players is expected to offer a potential opportunity to the single cell multiomics market over the projected period. For instance, in February 2025, Illumina, Inc. highlighted a number of roadmap advancements aimed at creating the industry's most comprehensive suite of omics and sequencing applications. The solutions, which encompass genomes, spatial transcriptomics, single-cell analysis, CRISPR technologies, epigenetics, and data analytics tools, will provide researchers with groundbreaking insights into disease causes. Because they are built on Illumina's powerful sequencers, the new omics solutions outperform industry standards for scalability, accuracy, and reliability.

The method will allow for single-cell readout of CRISPR activation, inactivation, or targeted gene editing, Perturb-seq investigations in a variety of intriguing applications, including cell atlasing and drug screening research. The kits are compatible with all Illumina sequencers, and the workflow incorporates DRAGEN Single Cell RNA Analysis for CRISPR gRNA screening using Illumina software.

Request Free Sample

Single Cell Multiomics Market: Challenges

Lack of standardization & protocol variation poses a major challenge to market expansion

The single cell multiomics sector fails to develop or expand as much as it could because there is a lack of established protocols. This problem directly affects the quality, repeatability, and comparability of results across studies and platforms, which makes it harder for clinical translation and public acceptability. Different labs, platforms, and types of omics use quite different approaches for preparing samples, breaking down cells, extracting nucleic acids, and building libraries. There is no one "best practice" for profiling RNA, DNA, and proteins in the same cell; therefore, different people come to different results.

Additionally, datasets are sometimes saved in formats that don't work with each other or don't include sufficient information on where the samples originated, how they were prepared, or the purpose of the experiment. It is hard to combine transcriptome, epigenomic, and proteomic data without clear explanations. Thus, hampering the single cell multiomics market.

Single Cell Multiomics Market: Report Scope

Single Cell Multiomics Market: Segmentation

The global single cell multiomics industry is segmented based on product, application, end-user, and region.

Based on the product, the global single cell multiomics market is bifurcated into single cell genomics, single cell proteomics, single cell metabolomics, and single cell transcriptomics. The single cell genomics segment is expected to hold the largest market share over the forecast period. This is because it provides previously unattainable levels of resolution, allowing for a more accurate understanding of cell activity and a better grasp of disease mechanisms. They have the potential to totally alter customized medicine by allowing for the identification of unusual cell types and biomarkers that would otherwise be overlooked in bulk sequencing, resulting in more accurate diagnoses and targeted treatments.

Based on the application, the global Single Cell Multiomics industry is bifurcated into immunology, cell biology, oncology, and neurology. The oncology segment is expected to hold the major chunk of the market share. This is because the industry invests in drug development and research for underprivileged patient populations, as well as for high-value indications. These objectives should be extremely marketable and provide a high return on investment. They should also leverage digital technologies like machine learning and artificial intelligence to improve patient monitoring and selection, dose optimization, and clinical trial design.

Based on the end-user, which segment will lead the global single cell multiomics market?

The industry is bifurcated into hospital and diagnostic laboratories, academic and research organizations, pharmaceutical & biotechnology companies, and others. The academic and research organizations segment is expected to capture a significant revenue share during the anticipated period. They frequently act as a catalyst for the development of new single-cell omics technologies and procedures. They conduct fundamental research to gain a deeper understanding of the biology of individual cells and develop new tools and methods for the molecular analysis of these cells. This study frequently leads to the development of new products and services, which biotech and pharmaceutical companies then sell.

Single Cell Multiomics Market: Regional Analysis

What factors help North America dominate the global single cell multiomics market?

North America is expected to dominate the market. The presence of important players in the region helps it maintain its greatest revenue share. Furthermore, organizations are making many efforts to increase their presence, which is driving regional market growth.

For instance, in May 2025, Pluto Bio raised USD 3.6 million to improve its AI-powered multi-omics platform for pharmaceutical applications. Pluto Bio's technology is already being used by mid-market and corporate clients in North America and Europe, seamlessly integrating into existing scientific processes and expanding the single cell multiomics industry.

Single Cell Multiomics Market: Competitive Analysis

The global single cell multiomics market is dominated by players like:

• 10x Genomics
• CELLENION
• PerkinElmer Inc.
• ANGLE plc
• Illumina Inc.
• Bio-Rad Laboratories Inc.
• Revvity
• Mission Bio
• BioTuring Inc.
• Singleron Biotechnologies
• AstraZeneca
• SIGNIOSBIO
• CYTENA GmbH
• BD
• Cellarity

The global single cell multiomics market is segmented as follows:

By Product

• Single Cell Genomics
• Single Cell Proteomics
• Single Cell Metabolomics
• Single Cell Transcriptomics

By Application

• Immunology
• Cell Biology
• Oncology
• Neurology

By End User

• Hospital and Diagnostic Laboratories
• Academic and Research Organizations
• Pharmaceutical & Biotechnology Companies
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa